Dr. Mark Lebwohl graduated summa cum laude from Columbia College in 1974 and graduated from Harvard Medical School in 1978. He completed residencies in internal medicine and dermatology, both at Mount Sinai. Dr. Lebwohl has been practicing dermatology since 1983. He is professor and chairman of the Kimberly and Eric J. Waldman Department of Dermatology of the Icahn School of Medicine at Mount Sinai. Dr. Lebwohl is the President of the American Academy of Dermatology. Dr. Lebwohl is chairman emeritus of the medical board of the National Psoriasis Foundation. He is the founding editor of Psoriasis Forum, as well as a medical editor of the bulletin of the National Psoriasis Foundation, Psoriasis Advance. He is editor of the Dermatology Section of Scientific American Medicine. Dr. Lebwohl has chaired numerous symposia and has written, edited or co-edited several books including Psoriasis, Mild-to-Moderate Psoriasis and Moderate-to-Severe Psoriasis. He has authored or co-authored over 500 publications including peer-reviewed articles, invited articles and book chapters. Dr. Lebwohl is actively involved in clinical trials of many new dermatologic treatments.
Tips in the Use of Anti-IL-17 Drugs for Psoriasis
- Recognize advantages of anti-IL-17 therapy
- Recognize clinical scenarios where anti-IL-17 therapy is ideal
- Analyze the long term past improvements of these drugs compared to other psoriasis therapies
- New advances in dermatologic treatment
- Availability of new medication(s) or indication(s)
- J Drugs Dermatol. 2017;17:247-50.
- JAAD. 2019;80:27-40.
Core Competencies: 2, 3, 4, 5, 6, 7
Disclosures: Abbvie, Amgen, Arcutis, Bausch Health (Valeant), Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Johnson & Johnson (Centocor, Janssen), Leo Pharmaceuticals, Medimmune/Astra Zeneca, Novartis, Pfizer (anacor), Regeneron, Sciderm, UCB, Inc., and ViDac. Consultant – Allergan, Aqua, Arcutis, Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, LEO Pharma, Menlo, Mitsubishi, Neuroderm, Promius, Theravance, and Verrica